A few months ago we investigated the use of unique biomarkers by big biopharma. The use of unique biomarkers served as a measure of innovation for each of the biggest biopharma companies. The most innovative companies are progressing biomarkers to trials more quickly than their less innovative competitors. In fact, on average, innovative biopharma companies are applying biomarkers to trials more than 2 years earlier than their less innovative competitors.
Share this Image On Your Site
Do you need similar analysis for your projects?